公开(公告)号：CA2038398A1

公开(公告)日：1992-09-16

申请号：CA2038398

申请日：1991-03-15

Applicant: RUBIN JEFFREY S ,  FINCH PAUL W ,  AARONSON STUART A

Inventor： RUBIN JEFFREY S ,  FINCH PAUL W ,  AARONSON STUART A

IPC: A61K39/395 ,  A61K38/00 ,  A61K38/18 ,  A61K38/22 ,  A61P17/02 ,  A61P43/00 ,  C07H21/04 ,  C07K1/16 ,  C07K14/00 ,  C07K14/435 ,  C07K14/47 ,  C07K14/475 ,  C07K14/485 ,  C07K14/50 ,  C07K16/00 ,  C07K16/22 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/08 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12N15/18 ,  C12N15/63 ,  C12N15/70 ,  C12N15/79 ,  C12P21/00 ,  C12P21/02 ,  C12Q1/68 ,  C12Q1/6876 ,  C12R1/91 ,  G01N33/48 ,  G01N33/50 ,  G01N33/53 ,  C12N15/62

Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.

公开(公告)号：AU5049690A

公开(公告)日：1990-08-24

申请号：AU5049690

申请日：1990-01-30

Applicant: AARONSON STUART A ,  FINCH PAUL W ,  RUBIN JEFFREY S

Inventor： RUBIN JEFFREY S ,  FINCH PAUL W ,  AARONSON STUART A

IPC: A61K39/395 ,  A61K38/00 ,  A61K38/18 ,  A61K38/22 ,  A61P17/02 ,  A61P43/00 ,  C07H21/04 ,  C07K1/16 ,  C07K14/00 ,  C07K14/435 ,  C07K14/47 ,  C07K14/475 ,  C07K14/485 ,  C07K14/50 ,  C07K16/00 ,  C07K16/22 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/08 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12N15/18 ,  C12N15/63 ,  C12N15/70 ,  C12N15/79 ,  C12P21/00 ,  C12P21/02 ,  C12Q1/68 ,  C12Q1/6876 ,  C12R1/91 ,  G01N33/48 ,  G01N33/50 ,  G01N33/53 ,  C07K3/18 ,  C07K13/00 ,  C07K7/06 ,  C07K7/08 ,  C12N5/00 ,  C12N15/00 ,  G01N33/536 ,  C07K7/10

Abstract: Discoveries are disclosed that show particular aspect or recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as product of antibodies. Means are described fro determining the level of expression of genes for the KGF protein, for example by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.

公开(公告)号：IE900358L

公开(公告)日：1990-07-31

申请号：IE35890

申请日：1990-01-31

Applicant: RUBIN JEFFREY S ,  FINCH PAUL W ,  AARONSON STUART A

IPC: C12N15/00 ,  C12P21/00 ,  C12Q1/02

公开(公告)号：CA1231608A

公开(公告)日：1988-01-19

申请号：CA488986

申请日：1985-08-19

Applicant: BRODSKY STUART A

Inventor： BRODSKY STUART A

IPC: A61B17/34

Abstract: A body constructed of resilient shape retentive material is provided and includes n peripheral frame of a first thickness and a membrane extending across the interior of the frame. The membrane is of a second thickness considerably less than the first thickness. The membrane includes a central opening therein and generally radial slots formed therein and extending outwardly from the opening toward the peripheral frame. Those portions of the membrane disposed between adjacent slots define generally triangular tongue portions. One side of the peripheral frame includes attaching structure in the form of pressure sensitive adhesive whereby the frame may be adhesively secured in overlying relation to the outer surface of the body skin portion. The opening may be used to receive a catheter or drain tube therethrough of a diameter greater than the diameter of the opening and with the free ends of the tongue portions disposed about the opening laterally deflected out of the plane of the remainder of the membrane and frictionally engaged with the catheter or drain tube. In this manner, the catheter or drain tube is frictionally retained against longitudinal shifting relative to the body.

公开(公告)号：GB8416545D0

公开(公告)日：1984-08-01

申请号：GB8416545

申请日：1984-06-28

Applicant: STUART A M

公开(公告)号：CA205863A

公开(公告)日：1920-11-23

申请号：CA205863D

Applicant: JONES STUART A

Inventor： JONES STUART A

公开(公告)号：ES3015758T3

公开(公告)日：2025-05-07

申请号：ES18841846

申请日：2018-07-31

Applicant: LIPTON STUART A

Inventor： LIPTON STUART A

IPC: A61K31/135 ,  A61K31/165 ,  A61K45/06 ,  A61P25/00 ,  G01N33/50 ,  G01N33/53 ,  H04R25/00

公开(公告)号：IL311965A

公开(公告)日：2024-06-01

申请号：IL31196524

申请日：2024-04-07

Applicant: DEKA PRODUCTS LP ,  ANDREWS RICHARD E ,  BIBEAU TRAVIS G ,  BOWDEN SCOTT R ,  BRADLEY MARGARET B ,  CANNAN DAVID D B ,  GLOEB MCDONALD ROBERT G ,  JACOBSON STUART A ,  JOHNSON HANS E ,  LOPRIORE DOMINIC P ,  MOREAU TIMOTHY D ,  NAEEM ALDEN S ,  NARO TREVOR M ,  NORRIS MATTHEW A ,  REMEC ANDREW G ,  SIMM DAVID A ,  VIOLETTE KEITH D

Inventor： ANDREWS RICHARD E ,  BIBEAU TRAVIS G ,  BOWDEN SCOTT R ,  BRADLEY MARGARET B ,  CANNAN DAVID D B ,  GLOEB-MCDONALD ROBERT G ,  JACOBSON STUART A ,  JOHNSON HANS E ,  LOPRIORE DOMINIC P ,  MOREAU TIMOTHY D ,  NAEEM ALDEN S ,  NARO TREVOR M ,  NORRIS MATTHEW A ,  REMEC ANDREW G ,  SIMM DAVID A ,  VIOLETTE KEITH D

IPC: F16H25/20

Abstract: A system and method to enable treatment through cell therapy. The system can enable cell injection such as, for example, injecting beta cells/islets, cartilage cells, fat cells, and others. The system and method ensure that the delivery rate and delivered volume of the material pumped through a tube and into the injection needle is consistent over the course of the start-operation-stop process from run to run. The system and method can automatically stop delivery and alarm if an occlusion is detected during delivery.

公开(公告)号：AU2018309710A1

公开(公告)日：2020-02-27

申请号：AU2018309710

申请日：2018-07-31

Applicant: LIPTON STUART A

Inventor： LIPTON STUART A

IPC: A61K31/135 ,  A61K31/165 ,  A61K45/06 ,  G01N33/50 ,  G01N33/53 ,  H04R25/00

Abstract: Disclosed herein are methods for treating juvenile onset neurological conditions, such as autism (ASD), intellectual disability, or epilepsy, with an inhibitor of N-methyl-D-aspartate receptor (NMDAR). The inhibitor may be NitroSynapsin or a derivative thereof.

公开(公告)号：CA2703316A1

公开(公告)日：2010-11-06

申请号：CA2703316

申请日：2010-05-06

Applicant: EMMONS STUART A

Inventor： EMMONS STUART A

IPC: C25B1/00

Abstract: This invention is directed toward process and material optimization of electrolytic cell separation processes designed to generate consistent electrolytic solutions in a better salt-converting and efficient manner, as well as to increase the amount of free available chlorine generated by the electro-chemical activation of the salt. This is generally accomplished by provision of ceramic diaphragm and/or polymer membranes characterized by optimal design, construction, manufacturing, and assemblage to exacting and precise specifications with respect to chemical and material compositions, slurry formulations, ceramic mold tolerances, ceramic firing and curing conditions, dimensional measurements for thickness, dimensional measurements for gapping and placement between the anode and cathode electrodes, and machining tolerance control.